卡瑞利珠单抗-话题@MedSci

#卡瑞利珠单抗#

14篇内容 | 2524人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1015862, encodeId=5d2e101586237, content=<a href='/topic/show?id=196b9e808ed' target=_blank style='color:#2F92EE;'>#阿帕替尼#</a>与<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>联合，毒性可能过大，还是T+A方案可能更好！除非阿帕替尼用小剂量！！, objectTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, objectType=article, longId=208916, objectId=dc73208916ac, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021323/1616492833763_2110107.PNG, objectUrl=/article/show_article.do?id=dc73208916ac, replyNumber=0, likeNumber=128, createdTime=2021-09-08, rootId=0, userName=病毒猎手, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc73208916ac, moduleTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc73208916ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909651, encodeId=24129096511a, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=阿帕替尼+卡瑞利珠单抗联合出击，为NSCLC患者带来新希望, objectType=article, longId=168141, objectId=9b1716814124, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201906/20190611211023855.jpg, objectUrl=/article/show_article.do?id=9b1716814124, replyNumber=0, likeNumber=114, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b1716814124, moduleTitle=阿帕替尼+卡瑞利珠单抗联合出击，为NSCLC患者带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b1716814124)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909650, encodeId=e1e89096508f, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, objectType=article, longId=194143, objectId=2d2a194143a2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200513/46e94c0c53ee42eda7414e18d6d0b6ee.jpg, objectUrl=/article/show_article.do?id=2d2a194143a2, replyNumber=0, likeNumber=132, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d2a194143a2, moduleTitle=Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d2a194143a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909649, encodeId=a13a9096497f, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, objectType=article, longId=193104, objectId=5d7319310411, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200420/94a119d961644e548119175cf8fd19f4.jpg, objectUrl=/article/show_article.do?id=5d7319310411, replyNumber=0, likeNumber=125, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d7319310411, moduleTitle=AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d7319310411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909648, encodeId=d87690964818, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！, objectType=article, longId=202292, objectId=ae1420229214, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201019/1603095070707_2110107.PNG, objectUrl=/article/show_article.do?id=ae1420229214, replyNumber=0, likeNumber=124, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae1420229214, moduleTitle=J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae1420229214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=909647, encodeId=9f5d90964ec8, content=<a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=卡瑞利珠单抗创造肺癌最长总生存期, objectType=article, longId=204726, objectId=e8bb204e26f4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201220/1608454899251_5268530.png, objectUrl=/article/show_article.do?id=e8bb204e26f4, replyNumber=0, likeNumber=125, createdTime=2020-12-20, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8bb204e26f4, moduleTitle=卡瑞利珠单抗创造肺癌最长总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8bb204e26f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卡瑞利珠单抗

2020-05-29

病毒猎手 (审核中...)

前往app查看评论内容

#阿帕替尼#与#卡瑞利珠单抗#联合，毒性可能过大，还是T+A方案可能更好！除非阿帕替尼用小剂量！！

J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果

2021-09-08

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

阿帕替尼+卡瑞利珠单抗联合出击，为NSCLC患者带来新希望

2020-12-20

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

Lancet Oncol：卡瑞利珠单抗二线治疗食管癌 III 期研究结果公布，患者死亡风险减少三成（ESCORT试验）

2020-12-20

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

AACR 2020：卡瑞利珠单抗+阿帕替尼治疗SCLC（小细胞肺癌）的II期研究

2020-12-20

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！

2020-12-20

lovetcm (审核中...)

前往app查看评论内容

#卡瑞利珠单抗#

卡瑞利珠单抗创造肺癌最长总生存期

2020-12-20

科室
- - 订阅+
  - 更多科室
工具
服务